Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06556732
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Potential Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective comparative study conducted at Cardiology Department Aswan University Hospital on AF patients with structural heart disease Eplerenone 25 mg daily will be given and searching for AF recurrence among study population
Detailed Description:
This is a prospective comparative study conducted at Cardiology Department Aswan University Hospital on 100 patients with AF and structural heart disease AF is confirmed by electrocardiography The patients were divided into 2 groups
Group A study group 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin
Group B control group 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin
Group A study group 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin
Group B control group 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None